Drugs / IN-A002
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05729074 | Feb 2023 | atopic eczema | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT05019755 | Aug 2021 → Feb 2022 | — | HK inno.N Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN-A002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05729074 ↗ |
| Known as | IN-115314 | “IN-A002(IN-115314) capsule” NCT05019755 ↗ |
| Route | Oral | “Oral Administration of IN-A002(IN-115314), single dose” NCT05019755 ↗ |